戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 molecular interventions in ocular von Hippel-Lindau disease.
2 tants may rescue pVHL function in von Hippel-Lindau disease.
3 erization and treatment of ocular von Hippel-Lindau disease.
4 hich can occur sporadically or in von Hippel-Lindau disease.
5  pathogenesis of renal cancer and von Hippel-Lindau disease.
6 gement, and treatment options for von Hippel-Lindau disease.
7 isposition to pheochromocytoma in von Hippel-Lindau disease.
8  should be screened for MEN-2 and Von Hippel-Lindau disease.
9 al cancer predisposition syndrome von Hippel-Lindau disease.
10  with or without association with von Hippel-Lindau disease.
11 tion in the VHL gene leads to the von Hippel-Lindau disease, a familial syndrome characterized by ben
12 protein (pVHL) is associated with von Hippel-Lindau disease, an inherited cancer syndrome, as well as
13       We studied 26 patients with von Hippel-Lindau disease and 9 patients with MEN-2 who had histolo
14  renal cancers in adults included von Hippel-Lindau disease and a rare form of chromosomal translocat
15 umors (ELSTs) are associated with von Hippel-Lindau disease and cause irreversible sensorineural hear
16 erial evaluation of patients with von Hippel-Lindau disease and ELSTs at the National Institutes of H
17         Thirty-five patients with von Hippel-Lindau disease and ELSTs in 38 ears (3 bilateral ELSTs)
18 e is inactivated in patients with von Hippel-Lindau disease and in most sporadic clear cell renal car
19                                   Von Hippel-Lindau disease and MEN-2 were diagnosed on the basis of
20  important in the pathogenesis of von Hippel-Lindau disease and RCC.
21  of the molecular pathogenesis of von Hippel-Lindau disease and the role of the VHL gene product (pVH
22  prior clinical manifestations of von Hippel-Lindau disease and, as expected, had germline von Hippel
23 (NF1), 444 tuberous sclerosis, 63 von Hippel-Lindau disease, and 39 ataxia-telangiectasia.
24 tiple endocrine neoplasia type 2, von Hippel-Lindau disease, and familial adenomatous polyposis are e
25 e predisposes patients to develop von Hippel-Lindau disease, and somatic VHL inactivation is an early
26            Patients affected with von Hippel-Lindau disease are at risk of developing multiple indepe
27 se may inform us as to how ocular von Hippel-Lindau disease arises, and help guide molecular interven
28 mutations have been found in both von Hippel-Lindau disease-associated and sporadic RCCs.
29             Adults with 1 or more von Hippel-Lindau disease-associated measurable renal cell carcinom
30 nts with an objective response in von Hippel-Lindau disease-associated renal cell carcinoma per Respo
31 ibitor belzutifan is approved for von Hippel-Lindau disease-associated renal cell carcinoma, CNS haem
32 zutifan as systemic treatment for von Hippel-Lindau disease-associated renal cell carcinoma.
33 ) mRNA is upregulated in RCC- and von Hippel-Lindau disease-associated tumors.
34 w-up for participants with ocular von Hippel-Lindau disease at baseline was 37.3 months.
35 ears or older with a diagnosis of von Hippel-Lindau disease (based on germline VHL alterations), at l
36 f renal cancer syndromes includes von Hippel-Lindau disease, Birt-Hogg-Dube syndrome, hereditary papi
37                               The von Hippel-Lindau disease gene (VHL) is the causative gene for most
38                  One patient with von Hippel-Lindau disease had a normal plasma normetanephrine conce
39 phrine, whereas the patients with von Hippel-Lindau disease had almost exclusively high plasma concen
40 inical characterization of ocular von Hippel-Lindau disease has been limited by small patient numbers
41         Genetic testing confirmed von Hippel-Lindau disease in 8 of 17 patients (47%).
42 promising activity against ocular von Hippel-Lindau disease, including capacity to control retinal he
43                                   von Hippel-Lindau disease is a hereditary cancer syndrome.
44                                   von Hippel-Lindau disease is a heritable multisystem cancer syndrom
45                                   von Hippel-Lindau disease is an inherited, multisystemic cancer syn
46 characterization of the impact of von Hippel-Lindau disease on eye health and visual function.
47          Twenty-one patients with von Hippel-Lindau disease or hereditary papillary renal cancer unde
48 hromocytomas and 50 patients with von Hippel-Lindau disease or MEN-2 who had no radiologic evidence o
49 heochromocytomas in patients with von Hippel-Lindau disease or MEN-2.
50 ese tumors, such as patients with von Hippel-Lindau disease or multiple endocrine neoplasia type 2 (M
51  2, von Recklinghausen's disease, von Hippel-Lindau disease, or Carney's syndrome.
52  on postmortem tissues from three von Hippel-Lindau disease patients (not in the clinical series).
53  with the clinical findings in 16 von Hippel-Lindau disease patients with 22 CNS hemangioblastomas (1
54 ance imaging (MRI) is obtained in von Hippel-Lindau disease patients, hemangioblastomas provide an op
55 creening studies in patients with von Hippel-Lindau disease should be interpreted cautiously because
56 argeting the molecular biology of von Hippel-Lindau disease, some of which are presently being invest
57                                   von Hippel-Lindau disease (VHL [MIM 193300]) is a heritable autosom
58 ses of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3
59                     Patients with von Hippel-Lindau disease (VHL) are at risk to develop multiple tum
60  meet the diagnostic criteria for von Hippel-Lindau disease (VHL) have a detectable inactivating germ
61                                   von Hippel-Lindau disease (VHL) is a dominantly inherited familial
62                                   von Hippel-Lindau disease (VHL) is an autosomal-dominant neoplasia
63 ne tumors (PNETs) associated with von Hippel-Lindau disease (VHL) is challenging because of the malig
64                                   Von Hippel-Lindau disease (VHL) is one of the most common inherited
65                                   von Hippel-Lindau disease (VHL) patients develop highly vascular tu
66 tiple endocrine neoplasia type 2, von Hippel-Lindau disease (VHL), and, very rarely, type 1 neurofibr
67 eochromocytoma susceptibility are von Hippel-Lindau disease (VHL), multiple endocrine neoplasia type
68 he promoter methylation status of von Hippel-Lindau disease (VHL), retinoic acid receptor beta (RAR-b
69 e in the general population, with von Hippel-Lindau disease (VHL).
70 linically and genetically defined von Hippel-Lindau disease was systemically characterized in a singl
71 e VHL tumor suppressor gene cause von Hippel-Lindau disease, which is associated with an increased ri